Beijing Pinggu District: Measures to Promote High-Quality Development of High-End Manufacturing

Mechanism

The measure applies to manufacturing enterprises registered and operating in Pinggu District, a peripheral district of Beijing, whose business scope matches the capital's strategic-industry positioning. It stacks several subsidy lines rather than a single instrument:

• Output growth (Art. 3): enterprises growing annual industrial output

≥5% get 0.5% of the output increment, capped at RMB 5 million.

• First-scale bonuses (Art. 4): enterprises first crossing RMB 100

million in annual output get up to RMB 300,000; newly-commissioned lines reaching that threshold get up to RMB 500,000.

• R&D (Art. 5): firms with R&D spend first reaching RMB 5 million get

up to RMB 300,000; firms sustaining ≥10% YoY R&D growth for two years get 10% of the R&D increment, capped at RMB 1 million/year.

• Smart-factory / "lighthouse factory" recognition (Art. 6): up to

RMB 2 million for World Economic Forum Lighthouse Factory status, lower tiers for national/municipal smart-manufacturing benchmarks.

• Green transformation (Art. 7): up to RMB 500,000 for national

"Green Factory" designation.

• Pharma / medical device innovation (Art. 10-11): up to RMB 3 million

per first-approved Class III medical device, RMB 3 million/2 million/1 million per new-drug/improved-drug/generic-drug registration; leading pharma firms sustaining >RMB 15 million/year R&D spend in-district for two years can get up to RMB 10 million — the largest single cap in the scheme.

• Auto-parts supply chain (Art. 12): 0.5% of incremental OEM order

value, capped at RMB 2 million, for parts suppliers deepening ties with EV manufacturers.

• Synthetic biology (Art. 13): 5% of qualifying fixed-asset investment

for synthetic-biology commercialisation projects, capped at RMB 3 million.

Article 21 sets the measure effective from its date of issuance with a two-year validity window (through roughly August 2027). It is one of a wave of Beijing sub-municipal/district-level industrial-subsidy schemes (cf. the sister Pinggu software/IT-services state-aid measure filed the same day) rather than a Beijing-municipality-wide or national program.

Downstream implications

• District-level, narrow-geography instrument — the per-recipient caps

(RMB 200K-10M) are small relative to municipal or national China industrial-policy programs, but the multi-sector reach (manufacturing, pharma/medtech, auto-parts, synthetic biology) and stacking of grant lines is representative of the dense layer of Chinese sub-provincial subsidy competition documented across many districts in 2025.

• The RMB 10 million leading-pharma-firm cap and RMB 3 million Class-III

medical-device cap are the most economically material single lines; worth tracking whether named recipients disclose under Pinggu's project-announcement process (Art. 14).

Open questions

• No public disclosure yet of first-round grant recipients or aggregate

disbursement under this scheme.

• Whether Pinggu's district-level program duplicates or stacks with any

Beijing-municipality-wide manufacturing subsidy scheme.